The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Belknap SM, Kuzel TM, Yarnold PR, Slimack N, Lyons EA, Raisch DW, Bennett CL

Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.

Cancer. 2006;106(9):2051-7

Kudrik FJ, Rivera MP, Molina PL, Maygarden S, Socinski MA

Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature.

Clinical lung cancer. 2002;4(1):52-6

Hammerer V, Schmitz N, Pauli G, Quoix E

[Interstitial lung disease in a patient given gemcitabine].

Revue de pneumologie clinique. 2002;58(1):23-6

Attar EC, Ervin T, Janicek M, Deykin A, Godleski J

Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000;18(3):697-8